--- title: "Contineum Therapeutics (CTNM) stock and investor profile" url: "https://aibio.space/companies/contineum-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Contineum Therapeutics, Inc. (NASDAQ: CTNM), United States. The directory classifies it as Biotechnology." --- CTNM Contineum Therapeutics, Inc. NASDAQ · United States # Contineum Therapeutics (CTNM) news Financings · 2026-03-05 ## [Contineum Therapeutics amends share sales deal, registers up to $100 million](https://aibio.space/news/contineum-therapeutics-amends-share-sales-deal-registers-up-100/) Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding. ## Latest Contineum Therapeutics news We have not published a story on Contineum Therapeutics yet. When there is news, it will appear here. ## Contineum Therapeutics at a glance - **Ticker**: CTNM - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $236.6 million ### Related companies - [Odyssey Therapeutics](https://aibio.space/companies/odyssey-therapeutics/) NASDAQ: ODTX - [NeoImmuneTech](https://aibio.space/companies/neoimmunetech/) KRX: 950220 - [Allogene Therapeutics](https://aibio.space/companies/allogene-therapeutics/) NASDAQ: ALLO - [Boundless Bio](https://aibio.space/companies/boundless-bio/) NASDAQ: BOLD - [Halberd](https://aibio.space/companies/halberd/) OTC: HALB - [AVVAA World Health Care Products](https://aibio.space/companies/avvaa-world-health-care-products/) OTC: AVVH - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NYSE: NUVB ### Also on NASDAQ - [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) FBIO - [NEXGEL, INC.](https://aibio.space/companies/nexgel/) NXGL - [KESTRA MEDICAL TECHNOLOGIES, LTD.](https://aibio.space/companies/kestra-medical-technologies/) KMTS - [Prothena Corporation](https://aibio.space/companies/prothena/) PRTA - [Coherus Oncology](https://aibio.space/companies/coherus-oncology/) CHRS - [NovoCure](https://aibio.space/companies/novocure/) NVCR ## Contineum Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$0](https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/) | | Research and development | [$51.5 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | [$38.4 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | | Net income (loss) | [-$60.0 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | [-$42.3 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | | Cash from operations | [-$55.3 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | [-$32.8 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | | Cash and equivalents | [$75.6 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051054/) | [$21.9 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | | Short-term investments | [$187.3 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051054/) | [$182.8 million](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $14.7 million, plus short-term investments of $221.8 million, $236.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Contineum Therapeutics What is the ticker symbol of Contineum Therapeutics? Contineum Therapeutics, Inc. trades under the ticker CTNM on NASDAQ. Where is Contineum Therapeutics listed? Contineum Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Contineum Therapeutics? The SEC Central Index Key (CIK) for Contineum Therapeutics, Inc. is 1855175. Its filings are on SEC EDGAR. How many shares does Contineum Therapeutics have outstanding? 23,099,173 shares as of 2025-10-27, per the cover page of its 10-Q filed 2025-10-30. Which country or territory is Contineum Therapeutics listed under? Our directory records Contineum Therapeutics, Inc. under United States. What does Contineum Therapeutics do? Our directory classifies Contineum Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Contineum Therapeutics? The ISIN recorded for Contineum Therapeutics, Inc. is US21217B1008. Does aibio.space cover Contineum Therapeutics? aibio.space lists Contineum Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Contineum Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Contineum Therapeutics profitable? Contineum Therapeutics, Inc. reported a net loss of $60.0 million for the fiscal year ended Dec 31, 2025, and used $55.3 million of cash in operations, per its annual report to the SEC. How much does Contineum Therapeutics spend on research and development? $51.5 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Contineum Therapeutics have? $236.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Contineum Therapeutics (CTNM) stock news? Our latest story on Contineum Therapeutics, dated Mar 5, 2026: "Contineum Therapeutics amends share sales deal, registers up to $100 million". Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding. [Source](https://aibio.space/news/contineum-therapeutics-amends-share-sales-deal-registers-up-100/). What is Contineum Therapeutics's latest stock offering or financing news? Our latest financing story, dated Mar 5, 2026: "Contineum Therapeutics amends share sales deal, registers up to $100 million". Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding. [Source](https://aibio.space/news/contineum-therapeutics-amends-share-sales-deal-registers-up-100/). Who were the underwriters or placement agents on Contineum Therapeutics's offering? From our story: The shares are sold at the market through Leerink Partners LLC as sales agent. [Source](https://aibio.space/news/contineum-therapeutics-amends-share-sales-deal-registers-up-100/). ## Investor discussion: Contineum Therapeutics Members talk about Contineum Therapeutics (CTNM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Contineum Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-05 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015205/contineum_prosuppatmamendm.htm) 2. 2025-12-11 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1855175/000143774925037553/ctnm20251210_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CTNM on TradingView](https://www.tradingview.com/symbols/NASDAQ-CTNM/). ## SEC filings and registration - **SEC name**: Contineum Therapeutics, Inc. - **CIK**: 1855175 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CTNM (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121 - **Phone**: (858) 333-5280 - **Shares outstanding**: 23,099,173 as of 2025-10-27 (10-Q filed 2025-10-30) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/ctnm-20260914.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051054/ctnm-20260630.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/ctnm-20260730.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1855175/000162828026048023/ctnm-20260713.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1855175/000162828026045804/ctnm-20260626.htm) filed 2026-06-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030614/ctnm-20260331.htm) filed 2026-05-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/ctnm-20260505.htm) filed 2026-05-05 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1855175/000162828026028881/ctnm-20260430.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001855175), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Contineum Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CTNM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Contineum Therapeutics, Inc. - **Ticker**: CTNM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US21217B1008 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CTNM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/contineum-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Contineum Therapeutics (CTNM) stock and investor profile", 2026-10-31, https://aibio.space/companies/contineum-therapeutics/